1. Scrip
  2. >>Business

Astellas Paying $5.9bn For Iveric To Boost Ophthalmology Presence

Eyes Post-Xtandi Revenues

 
• By Ian Haydock and Lisa Takagi

Astellas set to acquire private US firm to add to its strategic capabilities in ophthalmology focus area, along with another revenue pillar as it prepares for Xtandi expiry. 

Astellas notes a high expectation for Iveric Bio's clinical candidate ACP
Astellas eyes high-need ophthalmology indication and another revenue pillar in Iveric deal • Source: Shutterstock

Astellas Pharma, Inc. has entered into a definitive agreement to acquire US bioventure Iveric Bio for a total equity value of approximately $5.9bn, in a bid to enhance the Japanese major’s strategic presence in the ophthalmology area.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.